# Journal for ImmunoTherapy of Cancer

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/journal-for-immunotherapy-of-cancer/

## Facts

| Field | Value |
| --- | --- |
| Open Access | true |
| ISSN-L | 2051-1426 |
| ISSNs | 2051-1426 |
| OpenAlex ID | https://openalex.org/S2754803477 |
| Publisher | BMJ |

## Journal papers

Showing 12 of 44.

- [Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations](https://scholariq.org/papers/development-of-pd-1-and-pd-l1-inhibitors-as-a-form-of-cancer-immunotherapy-a/)
- [Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events](https://scholariq.org/papers/society-for-immunotherapy-of-cancer-sitc-clinical-practice-guideline-on-immune/)
- [Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project](https://scholariq.org/papers/establishing-guidelines-to-harmonize-tumor-mutational-burden-tmb-in-silico/)
- [Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment](https://scholariq.org/papers/inhibition-of-arginase-by-cb-1158-blocks-myeloid-cell-mediated-immune/)
- [A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable](https://scholariq.org/papers/a-multicenter-study-of-body-mass-index-in-cancer-patients-treated-with-anti-pd-1/)
- [PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma](https://scholariq.org/papers/pd1hi-cd8-t-cells-correlate-with-exhausted-signature-and-poor-clinical-outcome/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study](https://scholariq.org/papers/safety-and-antitumor-activity-of-dostarlimab-in-patients-with-advanced-or/)
- [Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion](https://scholariq.org/papers/tumor-derived-exosomal-hmgb1-fosters-hepatocellular-carcinoma-immune-evasion-by/)
- [Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/oncogene-specific-differences-in-tumor-mutational-burden-pd-l1-expression-and/)
- [Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma](https://scholariq.org/papers/multicenter-single-arm-phase-ii-trial-of-camrelizumab-and-chemotherapy-as/)
- [Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice](https://scholariq.org/papers/integrated-analysis-of-concomitant-medications-and-oncological-outcomes-from-pd/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.